• Blog Home
• Molecular
• News/Events
• Quality Control
• Stabilization
• Sed-rate

Why effective QC matters for sample-to-result instruments

Quality control for sample-to-result instruments is not optional, it’s essential. Missing a step or leaving a target out can compromise results and impact patient outcomes. Effective QC ensures instruments behave as expected under clinical conditions, giving laboratories confidence in every result.

Regulatory guidance and best practices consistently emphasize three critical principles for effective QC:

1. Patient-like performance: Controls should behave like real patient samples to ensure instruments respond accurately under clinical conditions. (ISO 15189 Section 5.6.2.2 – Quality control materials, CAP – Molecular Pathology Checklist; MOL.34220, MOL.34229, MOL.34270, MOL.34311)
2. End-to-end validation: Every stage of the assay — from lysis and extraction through amplification and detection — must be verified. (CAP – Molecular Pathology Checklist (MOL.34220, MOL.34229, MOL.34270, MOL.34311; Code of Federal Regulations Title 42: Public Health, Part 493: Laboratory Requirements (42 CFR 493))
3. Complete coverage: Controls should include all organisms the assay is designed to detect. Omitting any target creates blind spots in validation. (CLSI MM06-A2 Section 7.4.1- External Quality Control)

In short, robust QC behaves like patient samples, validates each step and includes all relevant targets. This is the standard upon which our controls are built.

Our sample-to-result instrument controls are designed to meet these principles directly:

• Patient-like performance: Controls behave like real patient samples, providing an accurate reflection of instrument performance.
• End-to-end validation: Every stage — from lysis and extraction through amplification and detection — is monitored, leaving no step unchecked.
• Complete organism coverage: Every organism that the assay is designed to detect is included, eliminating blind spots in validation.

It’s worth asking: does your current quality control truly validate every step and include all relevant organisms? Missing a target or skipping a step could leave blind spots that affect results.

If you’re considering controls that deliver patient-like performance, full step validation and complete organism coverage, we encourage you to take the next step in one of two ways:

• Not sure yet? Evaluate your current QC
  Evaluate your current controls against best practices and regulatory expectations.
• Already feeling like it’s time to switch? Book a time with us.
  Let’s talk about how our controls can close the gaps in your QC — and in some cases, we may even be able to offset validation costs to make the transition easier.

Evaluate your current QC

Quality control for sample-to-result instruments must do more than check a box — it must stand up to regulatory review and ensure patient confidence. Take this quiz to evaluate whether your current QC truly measures up.

Please enable JavaScript in your browser to complete this form.

Do you use external quality controls for sepsis testing? *

• Yes
• No

Do you use MDx-Chex® controls? *

• Yes
• No

matrix Does the

Is the control made to resemble actual patient samples (blood cells and culture matrix components)? *

• Yes
• No

Does the control monitor lysis, extraction, amplification AND detection? *

• Yes
• No

Are there stages of the assay that are not directly validated by your control? *

• Yes
• No

Does the control cover all organisms the assay is designed to detect? *

• Yes
• No

Are the organisms in the control intact? *

• Yes
• No

Does the control require pooling to reach comprehensive coverage? *

• Yes
• No

See your results